Back to Search
Start Over
[Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation].
- Source :
-
Bulletin du cancer [Bull Cancer] 2024 Jul-Aug; Vol. 111 (7-8), pp. 628-629. Date of Electronic Publication: 2024 May 13. - Publication Year :
- 2024
- Subjects :
- Humans
Female
Receptor, ErbB-2 genetics
Receptor, ErbB-2 metabolism
Mutation
Fulvestrant therapeutic use
Antineoplastic Agents, Hormonal therapeutic use
Receptors, Estrogen metabolism
Breast Neoplasms genetics
Breast Neoplasms pathology
Estrogen Receptor alpha genetics
Estrogen Receptor alpha metabolism
Subjects
Details
- Language :
- French
- ISSN :
- 1769-6917
- Volume :
- 111
- Issue :
- 7-8
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Editorial & Opinion
- Accession number :
- 38744543
- Full Text :
- https://doi.org/10.1016/j.bulcan.2024.03.005